1. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318–1330. doi:10.1056/NEJMoa061267
2. Hering BJ, Clarke WR, Bridges ND, et al; Clinical Islet Transplantation Consortium. Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. Diabetes Care. 2016;39:1230–1240. doi:10.2337/dc15-1988
3. Holmes-Walker DJ, Gunton JE, Hawthorne W, et al. Islet transplanta- tion provides superior glycemic control with less hypoglycemia com- pared with continuous subcutaneous insulin infusion or multiple daily insulin injections. Transplantation. 2017;101:1268–1275. doi:10.1097/ TP.0000000000001381
4. Schuetz C, Anazawa T, Cross SE, et al; IPITA YIC Young Investigator Committee. β cell replacement therapy: the next 10 years. Transplantation. 2018;102:215–229. doi:10.1097/ TP.0000000000001937
5. Mittal S, Johnson P, Friend P. Pancreas transplantation: solid organ and islet. Cold Spring Harb Perspect Med. 2014;4:a015610. doi:10.1101/ cshperspect.a015610
6. Wisel SA, Braun HJ, Stock PG. Current outcomes in islet versus solid organ pancreas transplant for β-cell replacement in type 1 dia- betes. Curr Opin Organ Transplant. 2016;21:399–404. doi:10.1097/ MOT.0000000000000332
7. McCall M, Shapiro AM. Update on islet transplantation. Cold Spring Harb Perspect Med. 2012;2:a007823. doi:10.1101/cshperspect.a007823
8. Najarian JS, Sutherland DE, Matas AJ, et al. Human islet transplanta- tion: a preliminary report. Transplant Proc. 1977;9:233–236.
9. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest. 2007;117:2553–2561. doi:10.1172/ JCI32959
10. Bugliani M, Masini M, Liechti R, et al. The direct effects of tacrolimus and cyclosporin A on isolated human islets: a functional, survival and gene expression study. Islets. 2009;1:106–110. doi:10.4161/isl.1.2.9142
11. Johnson JD, Ao Z, Ao P, et al. Different effects of FK506, rapa- mycin, and mycophenolate mofetil on glucose-stimulated insu- lin release and apoptosis in human islets. Cell Transplant. 2009;18:833–845. doi:10.3727/096368909X471198
12. Marzorati S, Melzi R, Citro A, et al. Engraftment versus immu- nosuppression: cost-benefit analysis of immunosuppression after intrahepatic murine islet transplantation. Transplantation. 2014;97:1019–1026. doi:10.1097/TP.0000000000000104
13. Gala-LopezBL,SeniorPA,KohA,etal.Latecytomegalovirustransmission and impact of T-depletion in clinical islet transplantation. Am JTransplant. 2011;11:2708–2714. doi:10.1111/j.1600-6143.2011.03724.x
14. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–940. doi:10.1056/ NEJMoa021744
15. Ryan EA, Paty BW, Senior PA, et al. Risks and side effects of islet transplantation. Curr Diab Rep. 2004;4:304–309. doi:10.1007/ s11892-004-0083-8
16. Wu PK, Park JI. MEK1/2 inhibitors: molecular activity and resist- ance mechanisms. Semin Oncol. 2015;42:849–862. doi:10.1053/j. seminoncol.2015.09.023
17. Seger R, Krebs EG. The MAPK signaling cascade. Faseb J. 1995;9:726–735.
18. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT fam- ily: regulation and function. Annu Rev Immunol. 1997;15:707– 747. doi:10.1146/annurev.immunol.15.1.707
19. Dumont FJ, Staruch MJ, Fischer P, et al. Inhibition of T cell activa- tion by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J Immunol. 1998;160:2579–2589.
20. Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014;11:385–400. doi:10.1038/nrclinonc.2014.83
21. Shindo T, Kim TK, Benjamin CL, et al. MEK inhibitors selectively sup- press alloreactivity and graft-versus-host disease in a memory stage- dependent manner. Blood. 2013;121:4617–4626. doi:10.1182/ blood-2012-12-476218
22. Itamura H, Shindo T, Tawara I, et al. The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects. JCI Insight. 2016;1:e86331. doi:10.1172/jci.insight.86331
23. Wang S, Guan Q, Diao H, et al. Prolongation of cardiac allograft survival by inhibition of ERK1/2 signaling in a mouse model. Transplantation. 2007;83:323–332. doi:10.1097/01.tp.0000251374.49225.19
24. Takahagi A, Shindo T, Chen-Yoshikawa TF, et al. Trametinib attenu- ates delayed rejection and preserves thymic function in rat lung trans- plantation. Am J Respir Cell Mol Biol. 2019;61:355–366. doi:10.1165/ rcmb.2018-0188OC
25. Toda Y, Kono K, Abiru H, et al. Application of tyramide signal ampli- fication system to immunohistochemistry: a potent method to local- ize antigens that are not detectable by ordinary method. Pathol Int. 1999;49:479–483. doi:10.1046/j.1440-1827.1999.00875.x
26. Miyagi T, Takehara T, Tatsumi T, et al. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer. 2003;106:81–89. doi:10.1002/ijc.11163
27. Ricordi C, Gray DW, Hering BJ, et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat. 1990;27:185–195. doi:10.1007/ BF02581331
28. Evgenov NV, Medarova Z, Pratt J, et al. In vivo imaging of immune rejection in transplanted pancreatic islets. Diabetes. 2006;55:2419–2428. doi:10.2337/db06-0484
29. Kant CD, Akiyama Y, Tanaka K, et al. Primary vascularization of allo- grafts governs their immunogenicity and susceptibility to tolerogenesis. J Immunol. 2013;191:1948–1956. doi:10.4049/jimmunol.1202092
30. Marino J, Paster J, Benichou G. Allorecognition by T lymphocytes and allograft rejection. Front Immunol. 2016;7:582. doi:10.3389/ fimmu.2016.00582
31. Brea EJ, Oh CY, Manchado E, et al. Kinase regulation of human MHC class I molecule expression on cancer cells. Cancer Immunol Res. 2016;4:936–947. doi:10.1158/2326-6066.CIR-16-0177
32. Ricordi C, Strom TB. Clinical islet transplantation: advances and immu- nological challenges. Nat Rev Immunol. 2004;4:259–268. doi:10.1038/ nri1332
33. Kanak MA, Takita M, Kunnathodi F, et al. Inflammatory response in islet transplantation. Int J Endocrinol. 2014;2014:451035. doi:10.115 5/2014/451035
34. Paraskevas S, Aikin R, Maysinger D, et al. Modulation of JNK and p38 stress activated protein kinases in isolated islets of Langerhans: insulin as an autocrine survival signal. Ann Surg. 2001;233:124–133. doi:10.1097/00000658-200101000-00018
35. Abdelli S, Ansite J, Roduit R, et al. Intracellular stress signaling path- ways activated during human islet preparation and following acute cytokine exposure. Diabetes. 2004;53:2815–2823. doi:10.2337/ diabetes.53.11.2815
36. Arnette D, Gibson TB, Lawrence MC, et al. Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic beta cells. J Biol Chem. 2003;278:32517–32525. doi:10.1074/jbc.M301174200
37. Lawrence MC, McGlynn K, Park BH, et al. ERK1/2-dependent activa- tion of transcription factors required for acute and chronic effects of glucose on the insulin gene promoter. J Biol Chem. 2005;280:26751– 26759. doi:10.1074/jbc.M503158200
38. Fei H, Zhao B, Zhao S, et al. Requirements of calcium fluxes and ERK kinase activation for glucose- and interleukin-1beta-induced beta- cell apoptosis. Mol Cell Biochem. 2008;315:75–84. doi:10.1007/ s11010-008-9791-8
39. Jin SM, Kim KS, Lee SY, et al. The sequential combination of a JNK inhibitor and simvastatin protects porcine islets from peritransplant apoptosis and inflammation. Cell Transplant. 2011;20:1139–1151. doi:10.3727/096368910X550170
40. Paraskevas S, Aikin R, Maysinger D, et al. Activation and expres- sion of ERK, JNK, and p38 MAP-kinases in isolated islets of Langerhans: implications for cultured islet survival. FEBS Lett. 1999;455:203–208. doi:10.1016/s0014-5793(99)00882-0
41. Noguchi H, Nakai Y, Ueda M, et al. Activation of c-Jun NH2-terminal kinase (JNK) pathway during islet transplantation and prevention of islet graft loss by intraportal injection of JNK inhibitor. Diabetologia. 2007;50:612–619. doi:10.1007/s00125-006-0563-2